The high-dose flu shot cut flu hospital admissions by 31% in French care homes, average age 88

Everyone in this study got a flu shot. That is what makes the result worth reading.

The question was not whether to vaccinate care home residents, which nobody disputes. It was whether the stronger of the two available products is worth the extra cost in the population that needs it most.

Writing in Age and Ageing, researchers matched 76,858 pairs of French nursing home residents with a mean age of 88 across the 2022-23 season. Influenza hospitalization rates were 302 versus 438 per 100 000 person-years, a difference of about 31% in favor of the high-dose vaccine.

Why a stronger dose exists at all

Vaccines work by showing the immune system a target and letting it rehearse. Older immune systems rehearse badly.

Older adults in nursing homes face high influenza-related morbidity and mortality due to immunosenescence and comorbidities, which may reduce vaccine effectiveness. Immunosenescence is the gradual decline in the immune system’s ability to respond to something new, and it is why the same shot that protects a 30-year-old well protects an 85-year-old less well.

The engineering answer is brute force. The high-dose product contains four times more antigen than standard-dose formulations, on the theory that a louder signal gets through a quieter system.

This study asks whether the theory pays off in the place it was designed for.

Reading a 31% that is not what it sounds like

Relative vaccine effectiveness is a comparison between two vaccines, not between a vaccine and nothing.

Both arms here were protected. The standard dose was already preventing a substantial number of admissions, and the 31% is the additional protection the high-dose product bought on top of that. It is not the vaccine’s total effect; it is the upgrade.

In absolute terms the gap is 136 hospital admissions per 100,000 person-years. In a population of a million nursing home residents that is a large number of ambulance journeys, and in a single home of eighty it is a difference nobody would notice.

Both readings are true, and the second is why this kind of finding matters at the level of national purchasing rather than individual choice.

The outcome that did not move

No significant relative effectiveness was observed for pneumonia or combined outcomes, and this is the part most likely to be misread as failure.

Pneumonia in an 88-year-old is usually not influenza. It is bacterial, or it follows a stroke, or it comes from aspiration. A flu vaccine can only prevent the fraction of pneumonia that flu causes, and in a broad pneumonia count that fraction is swamped.

An intervention that improved the outcome it targets and left an adjacent, mostly unrelated outcome alone is behaving the way a real effect behaves. The alarming version would have been the reverse.

What matching can and cannot fix

This is not a trial. Nobody assigned anyone a vaccine, and the reasons a French care home used one product rather than another in 2022 are not random.

The researchers matched pairs on sex, age group, region and vaccination week, which handles the obvious differences. It does not handle the ones nobody wrote down: how frail a particular resident was, how well staffed the home, whether the prescriber reserved the stronger product for the sickest residents or gave it to whoever was easiest to reach.

The authors say so plainly. Residual confounding cannot be excluded, and vaccine safety was not assessed in the present analysis. Their conclusion is a purchasing recommendation rather than a biological claim: the finding supports preferential high-dose use in this high-risk population.

What it means for anyone under 85

Less than the headline suggests, and that is worth saying clearly.

Mean age 88, living in residential care, in a country with near-universal vaccination in that setting. This is the frailest population in which a flu vaccine is routinely given, and it is precisely where a standard dose has the most room to underperform. A fit 70-year-old living at home is a different immune system with different room for improvement.

What does transfer is the ordinary advice underneath it. The flu can be serious or even deadly, especially for people over 65, newborn babies, and people with certain chronic illnesses, and the best way to prevent the flu is to get a flu vaccine every year. Vaccines teach your body’s immune system to recognize and defend against harmful germs, and this study is about how loudly you have to teach an older one.

For a family with a relative in residential care, the useful question is narrow and answerable: ask which flu vaccine the home uses.